Abstract
Cognitive impairment underpins some of the clinical spectrum of the cerebrovascular disease (CVD), as well as contributes to the patient´s impaired social and behavioral functioning, and the higher mortality. When cognitive function is affected by CVD, we name it as vascular cognitive impairment (VCI). The cognitive impairment may be mild, or may be severe enough to warrant a diagnosis of dementia. Pure vascular dementia is not common. Because of that the concept of mixed dementia has been included in the clinical diagnosis of VCI.
Despite a general emphasis in the international literature on the primary and secondary prevention of CVD to avoid vascular dementia or their combination with Alzheimer’s disease, the controversy concerning their diagnostic criteria and optimal treatment is still open. Given its growing burden, the prevention and treatment of CVD and the spectrum of VCI are critical priorities for clinical care and research.
We performed a selective review about the current status of vascular dementia, mild cognitive impairment due to CVD, and mixed dementia, with special emphasis on available evidence of pharmacological strategies for treatment and prevention from controlled clinical trials.
Keywords: Alzheimer's disease, cerebrovascular disease, post-stroke dementia, vascular cognitive impairment, vascular dementia, vascular risk factors.
Current Psychopharmacology
Title:Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Volume: 3
Author(s): Maria Julieta Russo and Ricardo Francisco Allegri
Affiliation:
Keywords: Alzheimer's disease, cerebrovascular disease, post-stroke dementia, vascular cognitive impairment, vascular dementia, vascular risk factors.
Abstract: Cognitive impairment underpins some of the clinical spectrum of the cerebrovascular disease (CVD), as well as contributes to the patient´s impaired social and behavioral functioning, and the higher mortality. When cognitive function is affected by CVD, we name it as vascular cognitive impairment (VCI). The cognitive impairment may be mild, or may be severe enough to warrant a diagnosis of dementia. Pure vascular dementia is not common. Because of that the concept of mixed dementia has been included in the clinical diagnosis of VCI.
Despite a general emphasis in the international literature on the primary and secondary prevention of CVD to avoid vascular dementia or their combination with Alzheimer’s disease, the controversy concerning their diagnostic criteria and optimal treatment is still open. Given its growing burden, the prevention and treatment of CVD and the spectrum of VCI are critical priorities for clinical care and research.
We performed a selective review about the current status of vascular dementia, mild cognitive impairment due to CVD, and mixed dementia, with special emphasis on available evidence of pharmacological strategies for treatment and prevention from controlled clinical trials.
Export Options
About this article
Cite this article as:
Russo Julieta Maria and Allegri Francisco Ricardo, Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating, Current Psychopharmacology 2014; 3 (1) . https://dx.doi.org/10.2174/2211556003666140702190144
DOI https://dx.doi.org/10.2174/2211556003666140702190144 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Neuromodulation for the treatment of psychiatric disorders
Neuromodulation techniques, including transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), magnetic seizure therapy (MST), electroconvulsive therapy (ECT), theta burst stimulation (TBS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS), have been widely employed in the therapeutic management of prevalent psychiatric conditions such ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relationship Between Level of Heart Type Fatty Acid Binding Protein (Before and after Procedures) with Acute Renal Failure after PCI in Patients Under PCI
Cardiovascular & Hematological Disorders-Drug Targets A Decade of Targets and Patented Drugs for Chemotherapy of Chagas Disease
Recent Patents on Anti-Infective Drug Discovery Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Modified Fibrin Hydrogel Matrices: Both, 3D-Scaffolds and Local and Controlled Release Systems to Stimulate Angiogenesis
Current Pharmaceutical Design Prevalence and Associated Risk Factors of Hyperglycemia and Diabetes Mellitus Among HIV Positive Patients in Tehran, Iran
Infectious Disorders - Drug Targets Withdrawal Notice: Morphology of Coronary Arteries in Relation to Ischemic Heart Disease
Current Pharmaceutical Design Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology CGRP, a Vasodilator Neuropeptide that Stimulates Neuromuscular Transmission and EC Coupling
Current Vascular Pharmacology Crossed Aphasia without Hemiparesis in a Dextral: A Case Report
New Emirates Medical Journal Direct Oral Anticoagulants use in Patients with Stable Coronary Artery Disease, Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Inflammation & Allergy - Drug Targets (Discontinued) Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
Current Vascular Pharmacology Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Endothelial Progenitor Cells at the Interface of Chronic Kidney Disease: From Biology to Therapeutic Advancement
Current Medicinal Chemistry Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews The Effect of Flavonoids on Allergic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry